about
Application of Oral Fluid Assays in Support of Mumps, Rubella and Varicella Control ProgramsEvaluation of the time resolved fluorescence immunoassay (TRFIA) for the detection of varicella zoster virus (VZV) antibodies following vaccination of healthcare workersPerformance of a time-resolved fluorescence immunoassay for measuring varicella-zoster virus immunoglobulin G levels in adults and comparison with commercial enzyme immunoassays and Merck glycoprotein enzyme immunoassayMeasurement of IgG antibodies to Chlamydia trachomatis by commercial enzyme immunoassays and immunofluorescence in sera from pregnant women and patients with infertility, pelvic inflammatory disease, ectopic pregnancy, and laboratory diagnosed ChlamPrevalence of anti-varicella-zoster virus antibodies in French infants under 15 months of age.Validity of a reported history of chickenpox in targeting varicella vaccination at susceptible adolescents in EnglandA review of the antimicrobial activity of the fluoroquinolones.Differentiation between wild-type and vaccines strains of varicella zoster virus (VZV) based on four single nucleotide polymorphisms.Is it appropriate to use fixed assay cut-offs for estimating seroprevalence?Ciprofloxacin resistance in methicillin- and gentamicin-resistant Staphylococcus aureus.Varicella zoster immune status in children treated for acute leukemia.Persistence of varicella-zoster virus viraemia in patients with herpes zoster.The sero-epidemiology of diphtheria in Western Europe. ESEN Project. European Sero-Epidemiology Network.Ceftazidime-resistant Klebsiella pneumoniae.Ramoplanin versus methicillin-resistant Staphylococcus aureus: in vitro experience.Viral load and antibody boosting following herpes zoster diagnosis.The differences in short- and long-term varicella-zoster virus (VZV) immunoglobulin G levels following varicella vaccination of healthcare workers measured by VZV fluorescent-antibody-to-membrane-antigen assay (FAMA), VZV time-resolved fluorescence iComparison of a commercial Varicella Zoster glycoprotein IgG enzyme immunoassay with a reference time resolved fluorescence immunoassay (VZV TRFIA) for measuring VZV IgG in sera from pregnant women, sera sent for confirmatory testing and pre and postThe seroepidemiology of Bordetella pertussis infection in Western EuropeEuropean Sero-Epidemiology Network: standardisation of the assay results for pertussisFollow-up of pregnant women exposed to chicken pox: an audit of relationship between level of antibody and development of chicken poxSeroprevalence of common vaccine-preventable viral infections in HIV-positive adultsApplication of a noninvasive oral fluid test for detection of treponemal IgG in a predominantly HIV-infected populationAn oral fluid test for syphilisDiphtheria immunity in adultsDiphtheria immunity in UK blood donorsBacteriological safety of cook-chill food at the Royal Free Hospital, with particular reference to ListeriaCytomegalovirus and Epstein-Barr Virus Associations with Neurological Diseases and the Need for Vaccine Development
P50
Q26774299-17B55C11-4570-447E-8BE1-ABA8F8110660Q33562829-6C18D48F-CE99-4509-BE11-14432F03C3DFQ34429296-D6315D3A-0208-44B3-8828-90D3F3E4D872Q35586678-599BAA00-B881-48AD-B2F7-462F46F0A0BCQ37156720-0C432FA3-2F85-4070-8BBB-5960A55C0D20Q37672263-2A9E77E2-6493-4648-A1EC-6E8C00324074Q37834318-6A44E5E5-17BD-4BA3-94AD-6A0341A58E9AQ40106448-B2D064DE-EDF4-4091-AAFB-824E66D92E94Q40603758-C05CEE81-ACD3-4921-A200-67D369543603Q41831148-3B00C65A-9CB2-4F11-8E32-018EEC0062D6Q42220932-68650961-752F-4127-955F-E053E31B804FQ45371111-7BE45D81-D821-4B8E-8268-910E91206B2FQ53331272-05D69D45-1E1C-4671-9821-5CC62097289EQ54294140-86CF60FC-3B7D-447C-94AC-182FC1D2AC23Q54337338-292AC0D9-59A7-42A4-85FF-F8D552F2C263Q55325101-E768A4B2-7424-42A5-A730-B49F3823F00AQ56767976-3FE4377B-21D7-4C06-A14C-98F080E2A66AQ56768005-BA6968B5-441E-4EF0-8135-8A4326E0BE48Q57385777-2678F882-B2D7-4F25-A10E-3E189CD52B51Q57385780-6F43DCD2-0683-42BC-A93B-F88EC8F9DB62Q62900517-3EE7B24C-9E24-401C-8998-2F0F6D17D334Q62900519-3746A5F4-9AC5-4315-A56D-883F42F795C7Q62900527-BE3F7D6B-C183-445B-88BA-CD800E405519Q62900531-9C54AB34-4078-4F42-B82C-7CD06BA2E21CQ62900544-E1724095-3873-4A8F-B063-54E8CFCCFD47Q62900547-CBE18DA3-6215-4FE8-8613-D89A7972AEB0Q62900557-CCE52B39-FDDC-4BE2-B433-91D7B3F22DD1Q92854437-3F003E68-EC30-4A30-A033-636E2C710721
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Peter Maple
@ast
Peter Maple
@en
Peter Maple
@es
Peter Maple
@nl
type
label
Peter Maple
@ast
Peter Maple
@en
Peter Maple
@es
Peter Maple
@nl
prefLabel
Peter Maple
@ast
Peter Maple
@en
Peter Maple
@es
Peter Maple
@nl
P106
P1153
6701823904
P31
P496
0000-0002-5534-5191